Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "Meta"

757 News Found

Effective corrosion management demands a holistic approach: Experts
News | November 04, 2025

Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability


Akums Drugs gets 20- year patent for
News | November 04, 2025

Akums Drugs gets 20- year patent for "Dual Release Gastro-Resistant Composition"

The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease


Lilly to build $3 billion oral medicine facility in Netherlands
News | November 04, 2025

Lilly to build $3 billion oral medicine facility in Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain


Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
Clinical Trials | October 31, 2025

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia


Lupin Digital Health launches VITALYFE
Healthcare | October 31, 2025

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce


Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
News | October 30, 2025

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs


MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
Clinical Trials | October 29, 2025

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation


GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Biotech | October 27, 2025

GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million

Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile